Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

Epigenomics. 2015 Oct;7(7):1083-8. doi: 10.2217/epi.15.66. Epub 2015 Nov 6.

Authors

James N Lowder¹, Pietro Taverna¹, Jean-Pierre J Issa²

Affiliations

¹ Astex Pharmaceuticals, 4420 Rosewood Drive, Suite 200, Pleasanton, CA 92488, USA.
² Fels Institute, Temple University School of Medicine & Cancer Epigenetics Program, Fox Chase Cancer Center, Temple Health, 3307 North Broad Street, Room 154, Philadelphia, PA 19140, USA.

PMID: 26541345
DOI: 10.2217/epi.15.66

No abstract available

Keywords: azacitidine; decitabine; guadecitabine; hypomethylating agents.

MeSH terms

Antimetabolites, Antineoplastic / pharmacokinetics
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / analogs & derivatives*
Azacitidine / pharmacokinetics
Azacitidine / therapeutic use
Cytidine Deaminase / antagonists & inhibitors*
Cytidine Deaminase / genetics
Cytidine Deaminase / metabolism
DNA Methylation / drug effects
DNA Modification Methylases / antagonists & inhibitors*
DNA Modification Methylases / genetics
DNA Modification Methylases / metabolism
Decitabine
Drug Design
Drug Resistance, Neoplasm / genetics
Drug Stability
Enzyme Inhibitors / pharmacokinetics
Enzyme Inhibitors / therapeutic use
Epigenesis, Genetic
Half-Life
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / pathology
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / genetics
Myelodysplastic Syndromes / metabolism
Myelodysplastic Syndromes / pathology
Randomized Controlled Trials as Topic

Substances

Antimetabolites, Antineoplastic
Enzyme Inhibitors
guadecitabine
Decitabine
DNA Modification Methylases
Cytidine Deaminase
Azacitidine